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Background
We sought to optimize the Nasal Allergen Challenge
(NAC) model to ensure reliability and repeatability of
results by modifying the qualifying criteria and allergen
concentration during the challenge.
Methods
20 Allergic Rhinitis (AR) participants underwent NAC
to determine the concentration at which a Total Nasal
Symptom Score (TNSS) of 10/12 OR a Peak Nasal
Inspiratory Flow (PNIF) reduction of 50 % was achieved.
4-fold increases in allergen concentration were adminis-
tered every 15 minutes until qualification criteria were
met. The Qualifying Allergen Concentration (QAC)
reached was used as a single challenge dose at the sub-
sequent NAC visit. 10 additional ragweed allergic and 4
non-allergic participants were qualified at a TNSS of
8/12 AND a PNIF reduction of 50%. Cumulative Aller-
gen Concentration (CAC) of all incremental doses was
used during the subsequent NAC visit. Participants
recorded TNSS and PNIF at baseline, 15 minutes,
30 minutes, 1 hour and hourly afterwards up to 12 hours
post-challenge during the NAC visit.
Results
QAC study participants qualifying only based on PNIF
reduction had significantly lower TNSS scores than those
qualifying on TNSS only or TNSS+PNIF (p<0.01). Parti-
cipants in both studies’ NAC visit reached peak TNSS at
15 minutes post-challenge followed by a gradual
symptom decline, while the “PNIF only” group had sig-
nificantly lower TNSS compared to others. All 3 groups
experienced a decline in peak TNSS following NAC com-
pared to screening, although groups qualifying on TNSS
and TNSS+PNIF maintained their PNIF scores.
Conclusion
The NAC model is well-suited to study AR symptoms.
TNSS and PNIF are complementary and must be inte-
grated in the qualifying criteria. Further protocol modifica-
tions, such as with multiple allergen challenges during the
NAC visit, may produce even more repeatable results.
Through optimizing the NAC protocol, the model
achieves reproducible results and becomes more reliable;
suitable for testing new medications in clinical trials.
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